BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

19 related articles for article (PubMed ID: 16697646)

  • 1. Anthranilic amide and imidazobenzothiadiazole compounds disrupt
    Smith J; Wescott H; Early J; Mullen S; Guzman J; Odingo J; Lamar J; Parish T
    Medchemcomm; 2019 Jun; 10(6):934-945. PubMed ID: 31303991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists.
    Naganawa A; Matsui T; Saito T; Ima M; Tatsumi T; Yamamoto S; Murota M; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
    Bioorg Med Chem; 2006 Oct; 14(19):6628-39. PubMed ID: 16784865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists.
    Naganawa A; Matsui T; Ima M; Yoshida K; Tsuruta H; Yamamoto S; Yamamoto H; Okada H; Maruyama T; Nakai H; Kondo K; Toda M
    Bioorg Med Chem; 2006 Dec; 14(23):7774-89. PubMed ID: 16931028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists.
    Asada M; Obitsu T; Nagase T; Sugimoto I; Yamaura Y; Sato K; Narita M; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem; 2009 Sep; 17(18):6567-82. PubMed ID: 19700331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further optimization of sulfonamide analogs as EP1 receptor antagonists: synthesis and evaluation of bioisosteres for the carboxylic acid group.
    Naganawa A; Matsui T; Ima M; Saito T; Murota M; Aratani Y; Kijima H; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Toda M
    Bioorg Med Chem; 2006 Nov; 14(21):7121-37. PubMed ID: 16879970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist.
    Blouin M; Han Y; Burch J; Farand J; Mellon C; Gaudreault M; Wrona M; Lévesque JF; Denis D; Mathieu MC; Stocco R; Vigneault E; Therien A; Clark P; Rowland S; Xu D; O'Neill G; Ducharme Y; Friesen R
    J Med Chem; 2010 Mar; 53(5):2227-38. PubMed ID: 20163116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new chemical leads for selective EP1 receptor antagonists.
    Naganawa A; Saito T; Nagao Y; Egashira H; Iwahashi M; Kambe T; Koketsu M; Yamamoto H; Kobayashi M; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M
    Bioorg Med Chem; 2006 Aug; 14(16):5562-77. PubMed ID: 16697646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EP1 antagonists for the treatment of inflammatory pain.
    Hall A; Billinton A; Giblin GM
    Curr Opin Drug Discov Devel; 2007 Sep; 10(5):597-612. PubMed ID: 17786859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analgesics and their antagonists: biochemical aspects and structure-activity relationships.
    Beckett AH; Casy AF
    Prog Med Chem; 1965 Feb; 4():171-218. PubMed ID: 5319798
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.